iPrevent is an online tool to help women understand their breast cancer risk and act on it.

What is iPrevent?

Every woman has an individual breast cancer risk dependent on many things they both can and cannot control such as family history, menopausal status, height, weight, and lifestyle factors such as diet and exercise. By knowing more about your risk and understanding how to change some modifiable factors, you can take appropriate actions to prevent or screen for breast cancer.

iPrevent is an online tool that has been built to help women understand their breast cancer risk and act on it. It has been created by Breast Cancer Trials (BCT) researchers, using data collected from international clinical trials. iPrevent has been created with the intention of facilitating prevention and screening discussions between women and their doctors. 

iPrevent should only be used by women without a personal risk of breast cancer, meaning women who have never received a breast cancer diagnosis.

How does iPrevent calculate my future risk of breast cancer?

iPrevent asks women, or their doctor, to enter family and personal history, lifestyle, and reproductive risk factor information. Using that information, it then provides ten year and residual life-time risk estimates. There are options to view this information as a pictogram or graph. It then provides tailored estimates of the absolute risk reductions for each breast cancer prevention strategy, personalised lifestyle change suggestions and tailored advice on breast cancer screening. There is an option to print out a summary for the woman to take to a consultation with her doctor, and/or so the doctor can incorporate it into the woman’s medical record.

What research is behind this risk calculator?

iPrevent is highly evidence based. It uses the well-validated IBIS and BOADICEA algorithms to estimate each woman’s person risk of breast cancer. An international prospective validation study, conducted using data on more than 16,000 women, has confirmed the accuracy of the risk estimates provided. It uses Cancer Australia guidelines to determine which risk management options women are advised about, based on their risk level. An Australian pilot study of women and doctors has also demonstrated that iPrevent has high usability and acceptability, and suggested that it improves knowledge without increasing anxiety.

How can doctors use iPrevent?

Focus groups conducted with doctors suggest that breast surgeons will find iPrevent particularly useful, not only for managing women at high or moderate risk of breast cancer, but also for reassuring those at average risk. Medical oncologists less frequently see women without a history of cancer, but questions about the risk of healthy family members, such as daughters and sisters often arise during medical oncology consultations. Medical oncologists may suggest that female family members consider using iPrevent and discuss the results with their GP. iPrevent also has an “Information for Clinicians” page that provides background information on the tool, references and tips that can help clinicians with the logistics of prescribing risk-reducing medication.

How is Breast Cancer Trials involved with iPrevent?

BCT provided the initial funding to commence the development of iPrevent, through the generosity of supporters, with further funding provided by the National Health and Medical Research Council. iPrevent was developed by a team of expert BCT doctors, researchers and consumers, including medical oncologist and breast cancer prevention expert, Professor Kelly-Anne Phillips who led the development of iPrevent, breast surgeon and BCT Director of Research Professor Bruce Mann, psychologist Professor Phyllis Butow, medical oncologist Associate Professor Ian Collins and Chair of the BCT Consumer Advisory Panel Ms Leslie Gilham.

Where can I find out more about iPrevent?

More information about the iPrevent tool at www.petermac.org/iPrevent or you can refer to the following publications on iPrevent.

Professor Kelly-Anne Phillips (pictured below) led the development of the iPrevent tool.

OlympiA was led in Australia by Breast Cancer Trials Study Chair and Peter MacCallum Cancer Centre Medical Oncologist, Professor Kelly-Anne Phillips.

iPrevent Publications


Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.

Gelber RD, Wang XV, Cole BF, Cameron D, Cardoso F, Tjan-Heijnen, Drop I, Loi S, Salgado R, Kiermaier A, Frank E, Fumagalli D, Caballero C, de Azambuja E, Procter M, Clark E, Restuccia E, Heeson, S, Bines J, Loible S, Piccart-Gebhart M, on behalf of the APHINITY Steering Committee and Investigators. European Journal of Cancer. 2022; 166219-228, https://doi.org/10.1016/j.ejca.2022.01.031, E-pub

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Lancet Oncology. 2022; epub 03 February 2022 E-pub

Treatment exposure and discontinuation in the PALbociclib coLlaborative Adjuvant Study of palbociclib with adjuvant endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer (PALLAS/AFT-05/ABCSG-42/BIG 14-03).

Mayer EL, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein HG, Zdenkowski N, Wette V, Miller KD, Balic M, Mayer IA, Cameron D, Winer EP, Lorenzo JJP, Lake D, Pristauz-Telsnigg G, Haddad UC, Shepher L, Iwata H, Goetz M, Cardoso F, Traina TA, Sabanathan D, Breitenstein U, Ackerl K, Metzger Filho O, Sehetner K, Solomon K, Sarra El-Abed, Puyana Theall K, Lu DR, Dueck A, Gnant M, DeMichele A. Journal of Clinical Oncology. 2022; 40(5):449-458, https://ascopubs.org/doi/abs/10.1200/JCO.21.02554?, Journal

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.

Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, BAdve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Piccart M, Roblin E, Michiels S. npj Breast Cancer. 2022; 8(3):epub 11 January 2022; , https://doi.org/10.1038/s41523-021-00362-1, E-pub

The Implementation of a Decision Aid for women with early-stage breast cancer considering prophylactic mastectomy: a pilot study. [BCT Discretionary Funding]

Jansen J, Serafimovska A, Glassey R, Zdenkowski N, Saunders C, Porter D, Butow P. Patient Education and Counseling. 2022; 105(1):74-80, https://doi.org/10.1016/j.pec.2021.04.033, E-pub


What are the barriers to assessment of ovarian toxicity in breast cancer clinical trials? [BCT Discretionary Funding].

Cui W, Phillips K-A, Francis PA, Loi S, Anderson RA, Partridge AH, Keogh LA. SABCS 2021; Abstract #P5-19-03, Abstract